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to-severe BPH completed three disease-speciﬁc instruments at
baseline and at follow-up visits: the International Prostate
Symptom Score (IPSS, a 7-item urinary symptom severity scale),
the BPH Impact Index (BII, a 4-item well-being scale associated
with BPH) and the PPSMQ (a 12-item instrument measuring
patient satisfaction in control of urinary symptoms, strength of
urinary stream, pain of urination and effect on usual activities
due to the pharmacotherapy). The psychometric performance,
including reliability, validity and responsiveness, of the PPSMQ
was analyzed. RESULTS: The mean age of the study sample was
66.7 years (n = 879). The PPSMQ demonstrated good internal
consistency (Cronbach’s alpha = 0.88 to 0.96) and reliability
(intraclass coefﬁcient = 0.37 to 0.40). Convergent validity of the
PPSMQ subscale and total scores measured by the Pearson coef-
ﬁcient ranged from 0.48 to 0.58 for the IPSS and 0.31 to 0.45 for
the BII, suggesting correlations between the PPSMQ and another
two logically-related instruments. The PPSMQ also demon-
strated discriminant validity against the IPSS, IPSS QoL item and
BII (F = 52.5, 42.3, and 26.9, respectively, p-values < 0.001). The
PPSMQ detected treatment differences between the monotherapy
and combination therapy arms: total scores at baseline for the
combination therapy, dutasteride and tamsulosin treatment
groups were 25.6, 25.8, and 25.7 (higher scores indicating lower
satisfaction), respectively; at two years, the scores were 17.8,
20.3, and 20.4, respectively. CONCLUSION: The PPSMQ dem-
onstrated good reliability, validity and responsiveness in measur-
ing patient satisfaction with the pharmacology treatments
for BPH. The PPSMQ may be an important addition to the
existing outcome measures used to assess BPH symptoms and
their treatments.
PUK22
ASSESSING PATIENT DESCRIPTIONS OF LOWER URINARY
TRACT SYMPTOMS (LUTS) AND PERSPECTIVES ON
TREATMENT OUTCOMES FORTHE DEVELOPMENT OF A
NEW LUTS PATIENT REPORTED OUTCOMETOOL
Coyne KS1, Sexton C1, Kopp Z2, Symonds T3,Aiyer L4, Kaplan S5,
Chapple C6,Wein AJ7
1United BioSource Corporation Center for Health Outcomes
Research, Bethesda, MD, USA, 2Pﬁzer, Inc, New York, NY, USA, 3Pﬁzer
Global Research & Development, Sandwich, Kent, UK, 4Pﬁzer Inc,
New York, NY, USA, 5Weill Cornell Medical College, Cornell
University, New York, NY, USA, 6The Royal Hallamshire Hospital,
Shefﬁeld, UK, 7University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVE: Although various instruments have been used to
assess the prevalence of LUTS, the interpretability of questions
from a patient perspective has not been assessed. There is a
need for qualitative research to inform the development of a
patient reported outcome (PRO) tool that assesses all LUTS.
METHODS: A series of eight focus groups and 66 cognitive
debrieﬁng interviews were conducted to elicit patient descrip-
tions of urinary symptoms and to assess treatment-seeking
behavior and treatment outcomes. Participants with a range of
LUTS were recruited from urology clinics and community set-
tings in different USA geographic regions. Trained interviewers
conducted each session following semi-structured interview
guides. Content and descriptive analyses were performed.
RESULTS: A total of 129 people (66 men, 63 women) partici-
pated. Mean age was 54 (26–80 y); 71% were white. Mean
symptom duration was 7 years for men; 15 years for women. A
wide range of LUTS were reported with participants generally
understanding and agreeing on the words used to describe most
LUTS. There were no differences in terminology used by clinical
and community participants. Some difﬁculty describing bladder
area pain, split stream, terminal dribble and post-micturition
dribble was noted. Most participants identiﬁed with the word
“bother” and thought it was important to assess both the fre-
quency and bother of each symptom. Reasons for seeking care
included symptom bother and fears about cancer and bladder
infections. When asked to describe a positive treatment outcome,
64% of participants responded that a 50% improvement in at
least one LUTS would be meaningful. A draft LUTS tool was
developed based on patient feedback. CONCLUSION: There is a
need for a new PRO tool to assess the frequency and bother of all
LUTS in terms understood by patients. A new LUTS PRO tool
was developed to include the patient perspective and is undergo-
ing validation.
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OBJECTIVE: Nocturia Quality of Life (N-QOL) questionnaire is
a self-administered, nocturia-speciﬁc, QoL instrument developed
to examine QoL impact of nocturia in male patients. This study
was designed to evaluate content and face validity of the N-QOL
in female patients. METHODS: Twenty women (mean age 59
years; range 27–83) diagnosed with nocturia (2 voids/night)
were recruited through U.S. urology clinics. To establish content
and face validity, the items and response options in the question-
naire must be considered relevant and comprehensive. The
N-QOL questionnaire was evaluated using 2 methodologies.
First, 15 patients provided information on their experiences of
the impact of nocturia on their QoL and reported the most
bothersome consequences of nocturia in a focus group format.
Patient responses were thereafter compared with N-QOL items
to evaluate how well they reﬂected the N-QOL concepts being
measured. Second, ﬁve patients directly evaluated the N-QOL in
an interview format using standardized cognitive debrieﬁng
methodology. RESULTS: Of the 20 participants (80% Cauca-
sian, 10% African-American, 10% Hispanic), 45% had their
condition for more than 5 years (45% had 3 voids/night and
25% 4 voids/night). Seventy percent had nocturia secondary to
OAB, and 30% were currently taking prescription medication
for the underlying cause of their nocturia. Disrupted sleep was
the most bothersome consequence of nocturia, which resulted
in sleeping longer into the daytime hours, being too tired to
exercise, eating at night, weight gain, difﬁculty concentrating,
and reduced productivity during daytime. This corresponded
well with N-QOL concepts. Directly evaluated the N-QOL was
found simple, clear, easy to complete, and comprehensive.
CONCLUSION: The N-QOL has face and content validity in
female nocturia patients, with sleep disruption causing severe
impact on daytime activities, as the most bothersome conse-
quence. The N-QOL items and response options are relevant and
comprehensive for assessing the impact of nocturia on QoL of
female patients.
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